Prospects for using a combination of a prebiotic and lactic acid for vaginal biotope correction
Objective. To evaluate the efficacy and safety of treatment and compliance in patients who use a vaginal gel that contains a combination of an oligosaccharide prebiotic (inulin) and lactic acid (salvagin) for bacterial vaginosis (BV) therapy. Subjects and methods. Clinical and molecular biological parameters before and after therapy with salvagin were determined in 30 patients with a diagnosis of BV based on both the Amsel criteria and the results of investigating the biological material by quantitative real-time polymerase chain reaction. Results. It was demonstrated that there was normalization of clinical and molecular biological parameters after using salvagin to treat BV. No adverse events were found during the treatment. The ease of using the drug was rated as good or excellent by 95% of the patients and as satisfactory by 5%. Conclusion. The use of the vaginal gel containing lactic acid ensures rapid elimination of clinical manifestations and normalization of laboratory indices in the treatment of BV, causes no undesirable effects, and shows high patient compliance.